SCHEMBL3010664

SCHEMBL3010664

COc1ccc(S(=O)(=O)C2CCN(c3nc(Cc4cc(F)cc(Cl)c4)cs3)CC2)c(OC)c1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.40
LMNA P02545 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
GPR6 P46095 1/20 0.36
P2RX7 Q99572 4/20 0.36
HSD17B10 Q99714 2/20 0.35
USP2 O75604 1/20 0.35
RECQL P46063 1/20 0.35
TP53 P04637 2/20 0.35
F2RL3 Q96RI0 4/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
AR P10275 1/20 0.34
CCR3 P51677 1/20 0.34
THRB P10828 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
F2 P00734 1/20 0.34
CYP19A1 P11511 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3014972 0.95 MAPT (0.38) MAPTLMNATDP1GPR6HSD17B10
SCHEMBL3016598 0.94 MAPT (0.43) MAPTLMNATDP1GPR6HSD17B10
SCHEMBL3011844 0.94 HSD17B10 (0.40) MAPTLMNATDP1GPR6P2RX7
SCHEMBL3014404 0.89 MAPT (0.39) MAPTLMNATDP1GPR6HSD17B10
SCHEMBL3009166 0.89 MAPT (0.39) MAPTLMNATDP1GPR6P2RX7
SCHEMBL3018015 0.89 MAPT (0.41) MAPTLMNATDP1P2RX7TP53
SCHEMBL3006527 0.88 ALDH1A1 (0.43) MAPTLMNATDP1HSD17B10RECQL
SCHEMBL3009170 0.88 MAPT (0.39) MAPTLMNATDP1GPR6HSD17B10
SCHEMBL3019179 0.88 MAPT (0.40) MAPTLMNATDP1GPR6HSD17B10
SCHEMBL3013857 0.88 ALDH1A1 (0.42) MAPTLMNATDP1GPR6HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885LMNA 80/4885TDP1 86/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.